LINCOLN, Neb., July 20, 2018 /PRNewswire/ -- LI-COR Biosciences announces an agreement with Vergent Bioscience, a cancer-focused biotechnology company, to license its IRDye QC-1 quencher technology and provide cGMP custom manufacturing services.
Vergent is developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and remove cancerous tissue during surgery.
"LI-COR has a proven track record in developing near-infrared technologies," says John Santini, Vergent's President & CEO. "In recent years LI-COR has expanded to offer a number of custom manufacturing services that align well with our needs."
"Vergent's unique application demonstrates yet another facet of the potential application of our proprietary technologies," says Bambi Reynolds, LI-COR's Associate Director of Business Development and Intellectual Property.
LI-COR offers more than 25 years of experience and innovation in the development of near-infrared imaging technologies. The company's product offerings now include products and custom services for probe development, image-guided surgery, and photodynamic therapy applications.
"Vergent is taking a leading-edge position with its work, and we appreciate the confidence they are placing in LI-COR with the selection of our product and manufacturing abilities," says Reynolds.
ABOUT VERGENT BIOSCIENCE, INC.
Vergent is a biotechnology company developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery. Surgery is often the first-line treatment for solid tumors and the prognosis of a procedure is highly correlated with achieving complete tumor removal. When injected prior to surgery, Vergent's molecularly-targeted probe binds to enzymes overexpressed in tumor tissue, activating a brightly fluorescing dye. The cancer "lights up," providing the surgeon a clear visual guide for the surgical removal of the tumor and associated metastases. Vergent's proprietary probe is under development for use in multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. For more information, visit: https://www.vergentbio.com/.
ABOUT LI-COR Biosciences
LI-COR introduced the world's first near-infrared DNA sequencer for non-clinical research use in 1992 and has continued to develop innovative solutions for pre-clinical and basic science research including targeting agents and instrumentation for disease research as well as small animal live imaging. LI-COR IRDye infrared dye technology is currently involved in more than 20 human clinical trials worldwide for potential therapeutic and diagnostic applications including cancer treatments and surgical visualization. The company also offers research and manufacturing custom services for imaging agents used in basic research, pre-clinical, and early phase clinical studies.
SOURCE LI-COR Biosciences